Adherence of Apixaban and Warfarin in Patients With Arterial Fibrillation in Real-world Setting in Sweden

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Anticoagulation

Study type: Observational

Funder types: Industry

Identifiers

NCT02492828

CV185-323

Details and patient eligibility

About

This will be a retrospective cohort study using national register linkage data (including prescription, inpatient, mortality, and socioeconomic data). The study period will be from May 29, 2013 to June 30, 2015. Patients will be followed from the start of treatment (index date) until their death, exiting the database, or until the end of the study period (June 30, 2015).

Enrollment: 41,000 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• For the AF cohort

  • Patients that have ≥1 AF diagnosis registered in the patient register

• Apixaban subcohort 1

  • Patients eligible for the AF cohort
  • Patients that had a first prescription for apixaban during the identification period without previous prescriptions for NOACs or warfarin during the preceding 12 months

• Warfarin subcohort 1

  • Patients eligible for the AF cohort
  • Patients that had a first prescription for warfarin during the identification period without previous prescriptions for NOACs or warfarin during the preceding 12 months

• Apixaban subcohort 2

  • Patients eligible for the AF cohort
  • Patients that had a first prescription for apixaban during

Exclusion criteria

• For the AF cohort:

  • Patients with valvular AF will be excluded (see definition Appendix 1)

• Warfarin subcohort 1:

  • Patients will be excluded from this sub-cohort if they had at least one prescription for warfarin or NOACs during the 12-month period preceding the first prescription for warfarin during the identification period, ie, the index date

Trial design

41,000 participants in 2 patient groups

Patients for filled prescriptions for apixaban

Patients for filled prescriptions for warfarin